ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ジクロロメチレンビス(ホスホン酸)

Clodronate

HCID 25419
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
10596-23-3
標準SMILES
O=P(O)(O)C(Cl)(Cl)P(=O)(O)O
InChIKey
ACSIXWWBWUQEHA-UHFFFAOYSA-N
分子式
CH4Cl2O6P2
平均分子量
244.89 g/mol
単同位体質量
243.8860172

概要

Clodronic acid is an organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases. It has a role as an antineoplastic agent and a bone density conservation agent. It is an organochlorine compound, a one-carbon compound and a 1,1-bis(phosphonic acid). It is a conjugate acid of a clondronate(2-).

名称と識別子

優先名称
Clodronate
IUPAC
[dichloro(phosphono)methyl]phosphonic acid
現地名
ジクロロメチレンビス(ホスホン酸)
英語名
Clodronic acid
分子式
CH4Cl2O6P2
分子量
244.89

名称と別名

Clodronic Acid10596-23-3Clodronate(Dichloromethylene)diphosphonic acidAcido clodronicoAcide clodroniqueAcidum clodronicumClodronsaeure[dichloro(phosphono)methyl]phosphonic acidDichloromethylidene diphosphonate(Dichloromethylene)bisphosphonic acidDichloromethanediphosphonic acid
名称をさらに表示
ジクロロメチレンビス(ホスホン酸)ジクロロメチレンビスホスホン酸クロドロナート(ジクロロメチレン)ビスホスホン酸クロドロン酸(ジクロロメチレン)ビス(ホスホン酸)[ジクロロ(ホスホノ)メチル]ホスホン酸ジクロロ[α,β-メチレン]二りん酸diphosphonic acidClodronicDichloromethylenebisphosphonic acid(Dichloromethylene)bis(phosphonic acid)ARC-69931Aids071014Aids-071014Clodronate AcidClodronic acid 18O3
Phosphonic acid, (dichloromethylene)bis-ClasteonLoron(Dichloro-phosphono-methyl)-phosphonic aciddichloromethylene-1,1-diphosphonic aciddichloromethylene-1,1-bisphosphonic acidDTXSID8046959Acid, Clodronic

物性

構造計算による物性

XLogP
-2.1
極性表面積
115 Ų
水素結合供与体数
4
水素結合受容体数
6
回転可能結合数
2
重原子数
11
形式電荷
0
複雑度
211

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP-2.4
Solubility7.47e+00 g/L
Animal Drugs · 2 件

FDA approved animal drugs -> Active ingredient

Pharmaceuticals -> UK Veterinary Medicines Directorate List

Melting Point250 °C
Physical DescriptionSolid

物理化学的性質

融点
249 · 249-251°
沸点
474.7 · 474.7±55.0 °C(Predicted)
比重(密度)
2.306 · 2.306±0.06 g/cm3(Predicted)
貯蔵温度
2 · under inert gas (nitrogen or Argon) at 2-8°C
外見
Solid
酸解離定数(Pka)
0.75 · 0.75±0.10(Predicted)
色
Off-white to light yellow
InChI
InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

Health EffectsDecreases in serum calcium following substantial overdosage may be expected in some patients.
Exposure RoutesOral, Intravenous. After oral administration, absorption is estimated at 1–3% of the ingested dose because of the low uptake from the gastrointestinal tract.
Toxicity Summary · 1 件

The bisphosphonate group binds strongly to the bone mineral, hydroxyapatite. This explains the specific pharmacological action of these compounds on mineralized tissues, especially bone. The exact mechanism of action of clodronate is not known, however it is known that it does not inhibit protein isoprenylation but can be metabolized intracellularly to a &beta;-&gamma;-methylene (AppCp-type) analog of ATP (AppCCl2p), which is cytotoxic to macrophages in vitro. Inhibition of the ADP/ATP translocase by the metabolite AppCCl2p is a likely route by which clodronate causes osteoclast apoptosis and inhibits bone resorption. Recently, the slime mold <i>Dictyostelium discoideum</i> was shown to take up bisphosphonates by pinocytosis. In these cells, clodronate, but not other pharmacologically active bisphosphonates, was incorporated into adenine nucleotides, which could potentially explain why this bisphosphonate sometimes seems to act differently than the other bisphosphonates. Clodronate, like all biphosphonates, also binds protein-tyrosine-phosphatase.

Signs and SymptomsSigns and symptoms of hypocalcemia also may occur in some of these patients.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 4 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Clodronic acid

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

安全データ

注意喚起語

化学と産業

薬理情報

ATC Code · 3 件

M05BA02

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingClodronic acid is 36% protein bound in plasma.
Pharmacodynamics · 1 件

Clodronic acid is a first generation bisphosphonate that inhibits osteoclast mediated bone resorption. It has a wide therapeutic index as a large overdose is required for significant toxicity and a long duration of action due to the slow release from bone. Patients should be counselled regarding the risk of hypocalcemia, hypovolemia, renal insufficiency, transient hyperphosphatemia, and transient hyperparathyroidism.

Mechanism of Action · 1 件

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. First generation bisphosphonates closely mimic the structure of pyrophosphate, which can be incorporated into ATP anologues that cannot be hydrolyzed, disrupting all ATP mediated actions of osteoclasts.

Biological Half-LifeThe mean plasma half life of clodronate is 5.6h.
Metabolism/Metabolites · 2 件

Clodronate is not metabolized in humans.

Clodronate is not metabolized in humans. It can be metabolized intracellularly to a beta-gamma-methylene (AppCp-type) analog of ATP (AppCCl2p), which is cytotoxic to macrophages in vitro. Half Life: Approximately 13 hours.

MeSH Pharmacological ClassificationAgents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.

関連反応

7 件
反応記録を作成
HRID 431286 の反応式
HRID 431286反応物として
HRID 1157346 の反応式
HRID 1157346生成物として
HRID 1181911 の反応式
HRID 1181911生成物として
HRID 1182403 の反応式
HRID 1182403反応物として
HRID 1602952 の反応式
HRID 1602952反応物として
HRID 1602975 の反応式
HRID 1602975反応物として
HRID 1817514 の反応式
HRID 1817514生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
10596-23-3
PubChem CID
25419
DTXSID
DTXSID8046959
ChEMBL
CHEMBL12318
ChEBI
CHEBI:110423
UNII
0813BZ6866
EC Number
234-212-1
Nikkaji
J10.448E
InChIKey
ACSIXWWBWUQEHA-UHFFFAOYSA-N
SMILES
C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl
危険
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H290
Absorption, Distribution and Excretion · 3 件

Oral clodronic acid has a bioavailability of 1-2%. A 200mg intravenous dose reaches a Cmax of 16.1mg/L with an AUC of 44.2mg\*h/L. A 200mg intramuscular dose reaches a Cmax of 12.8mg/L with an AUC of 47.5mg\*h/L. Further pharmacokinetic data for clodronic acid are not readily available.

Clodronate is eliminated unchanged in the urine.

The renal clearance of clodronate is approximately 90mL/min.

Cellular LocationsCytoplasm

用途と製造

Uses · 2 件

Use (kg; approx.) in Germany (2009): >500

A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. For the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors.

応用分野

使用Clodronic Acid is a bisphosphonate that can be used in the treatment of osteoporosis. Its ATP-analogs can inhibit cell signaling pathways.

上流・下流製品情報

上流原料

ジブロモメタン
補足説明 · 1 件

定義ChEBI: An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the trea ment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.